Back to Search
Start Over
Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.
- Source :
-
Tumori [Tumori] 2013 Sep-Oct; Vol. 99 (5), pp. e241-4. - Publication Year :
- 2013
-
Abstract
- Gefitinib is the current first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as neoadjuvant therapy is interesting because of the low toxicity profile of tyrosine kinase inhibitors. Here we report the case of a 67-year-old nonsmoking woman affected by locally advanced lung adenocarcinoma, in whom one-year treatment with gefitinib rendered the tumor amenable to surgical removal. The results of ongoing clinical trials exploring the ability of preoperative gefitinib to achieve better results than can be obtained with chemotherapy in patients selected on the basis of EGFR mutations are urgently awaited.
- Subjects :
- Adenocarcinoma genetics
Adenocarcinoma pathology
Adenocarcinoma of Lung
Aged
Chemotherapy, Adjuvant
Female
Gefitinib
Humans
Lung Neoplasms genetics
Lung Neoplasms pathology
Polymerase Chain Reaction
Positron-Emission Tomography
Tomography, X-Ray Computed
Treatment Outcome
Adenocarcinoma drug therapy
Adenocarcinoma surgery
Antineoplastic Agents therapeutic use
ErbB Receptors genetics
Lung Neoplasms drug therapy
Lung Neoplasms surgery
Mutation
Neoadjuvant Therapy methods
Protein Kinase Inhibitors therapeutic use
Quinazolines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2038-2529
- Volume :
- 99
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Tumori
- Publication Type :
- Academic Journal
- Accession number :
- 24362878
- Full Text :
- https://doi.org/10.1700/1377.15324